BioCentury
ARTICLE | Financial News

Chinese CAR-T play CARsgen raises $30M

January 26, 2016 2:14 AM UTC

CARsgen Therapeutics Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by KTB Ventures and Jolly Innovation Ventures. Kaitai Capital and JIC GenesisFountain Healthcare Ventures also participated.

CARsgen is developing chimeric antigen receptor (CAR) T cell therapies for solid tumors. This year, the biotech plans to complete Phase I trials in China of CSG- GPC3 ( KJgpc3-001) to treat hepatocellular carcinoma (HCC) and CSG- EGFR to treat malignant glioblastoma that overexpresses EGFR. Data from both trials are expected in December. ...